Investigation Report on China Gliclazide Market, 2010-2019
Description
According to the statistics of International Diabetes Federation (IDF), in 2013, the prevalence of diabetes among adults aged from 20 to 79 was 8.3% and the number of diabetes patients has reached 382 million in the world, 80% of which come from middle income and low income countries and the figure demonstrates a fast rising trend. It is estimated that by 2035, there will be nearly 592 million people suffering from diabetes in the whole world. The number of diabetes patients in China was estimated to be 98.4 million in 2013, ranking first in the world, followed by India (65.1 million), USA (24.4 million), Brazil (11.9 million) and Russia (10.9 million). IDF estimates that by 2035, the number of diabetes patients in China will reach 143 million, still ranking first in the world while that in America will reach 29.7 million. The fast growth of diabetes in China and other developing countries has put a heavy burden on their social and economic development.
As one of the earliest oral antidiabetic drugs, sulfonylurea is common to patients with insulin hyposecretion. By stimulating insulin secretion, sulfonylurea is able to reduce blood glucose. According to the length of action, sulfonylurea can be categorized into short-acting, medium-acting and long-acting preparations. And glibenclamide, gliquidone, gliclazide and glimepiride are the common drugs in the class of sulfonylurea.
First developed by Servier (France), gliclazide entered China in 1985. Gliclazide acts in a mild way and since it can inhibit platelet aggregation and thrombosis as well as lower blood viscosity, it both reduces blood glucose and prevents microangiopathy. Before Servier (France) developed gliclazide sustained-release tablet which should be given at a dose of 30 mg once daily in Nov. 2000 only gliclazide immediate-release tablet, a 80 mg formulation that should be taken in two divided doses daily, was available in the market.
Although over ten local enterprises got the approval to produce gliclazide, they all took up a small market share, among which Servier (Tianjin) Pharmaceutical Co., Ltd ranked first despite a share of less than 2% due to the support from Servier (France) that began to cooperate with it in 1987 to produce gliclazide sustained release tablet.
According to CRI’s market survey, in 2014, Servier (France) and its subsidiary Servier (Tianjin) Pharmaceutical Co., Ltd took up a market share of about 96% for sales value in China while other companies like Tianjin Huajin Pharmaceutical Co., Ltd, Helioeast and Beijing Wansheng Pharmaceutical Co., Ltd shared the rest market share. The sales value of gliclazide was about CNY 137 million in 2014 and CAGR reached 12% during the period of 2005-2014.
The market size of gliclazide is expected to keep growing in the next few years in China.
Readers can get at least the following information through this report:
According to the statistics of International Diabetes Federation (IDF), in 2013, the prevalence of diabetes among adults aged from 20 to 79 was 8.3% and the number of diabetes patients has reached 382 million in the world, 80% of which come from middle income and low income countries and the figure demonstrates a fast rising trend. It is estimated that by 2035, there will be nearly 592 million people suffering from diabetes in the whole world. The number of diabetes patients in China was estimated to be 98.4 million in 2013, ranking first in the world, followed by India (65.1 million), USA (24.4 million), Brazil (11.9 million) and Russia (10.9 million). IDF estimates that by 2035, the number of diabetes patients in China will reach 143 million, still ranking first in the world while that in America will reach 29.7 million. The fast growth of diabetes in China and other developing countries has put a heavy burden on their social and economic development.
As one of the earliest oral antidiabetic drugs, sulfonylurea is common to patients with insulin hyposecretion. By stimulating insulin secretion, sulfonylurea is able to reduce blood glucose. According to the length of action, sulfonylurea can be categorized into short-acting, medium-acting and long-acting preparations. And glibenclamide, gliquidone, gliclazide and glimepiride are the common drugs in the class of sulfonylurea.
First developed by Servier (France), gliclazide entered China in 1985. Gliclazide acts in a mild way and since it can inhibit platelet aggregation and thrombosis as well as lower blood viscosity, it both reduces blood glucose and prevents microangiopathy. Before Servier (France) developed gliclazide sustained-release tablet which should be given at a dose of 30 mg once daily in Nov. 2000 only gliclazide immediate-release tablet, a 80 mg formulation that should be taken in two divided doses daily, was available in the market.
Although over ten local enterprises got the approval to produce gliclazide, they all took up a small market share, among which Servier (Tianjin) Pharmaceutical Co., Ltd ranked first despite a share of less than 2% due to the support from Servier (France) that began to cooperate with it in 1987 to produce gliclazide sustained release tablet.
According to CRI’s market survey, in 2014, Servier (France) and its subsidiary Servier (Tianjin) Pharmaceutical Co., Ltd took up a market share of about 96% for sales value in China while other companies like Tianjin Huajin Pharmaceutical Co., Ltd, Helioeast and Beijing Wansheng Pharmaceutical Co., Ltd shared the rest market share. The sales value of gliclazide was about CNY 137 million in 2014 and CAGR reached 12% during the period of 2005-2014.
The market size of gliclazide is expected to keep growing in the next few years in China.
Readers can get at least the following information through this report:
- market size of gliclazide in China
- major manufacturers of gliclazide for Chinese market and their market share
- retail price of gliclazide in Chinese market
- market outlook of gliclazide in China
- manufacturers of anti-diabetic drugs
- investors/ research institutions interested in Chinese medicine market
- any interest in the medicine market, please contact CRI for customized survey service
1 RELATED CONCEPTS OF GLICLAZIDE
1.1 Indication
1.2 Sales Status in Global Market
2 MARKET PROFILE OF GLICLAZIDE IN CHINA
2.1 Patent Status
2.2 Major Manufacturers
2.3 Market Size
3 SURVEY ON SALES STATUS OF GLICLAZIDE IN CHINA, 2010-2014
3.1 Sales Value
3.1.1 Overall Sales Value
3.1.2 Sales Value by Regions
3.2 Sales Volume
3.2.1 Overall Sales Volume
3.2.2 Sales Volume by Regions
4 SURVEY ON MARKET SHARE OF MAJOR MANUFACTURERS OF GLICLAZIDE IN CHINA, 2010-2014
4.1 Market Share by Sales Value
4.2 Market Share by Sales Volume
5 SURVEY ON DOSAGE FORMS OF GLICLAZIDE IN CHINA, 2010-2014
5.1 Share of Different Dosage Forms by Sales Value
5.2 Share of Different Dosage Forms by Sales Volume
6 REFERENCE PRICE OF GLICLAZIDE IN CHINESE HOSPITALS IN 2014
6.1 Servier (Tianjin) Pharmaceutical Co., Ltd (Trade Name: Diamicron)
6.2 Servier (France)
6.3 Tianjin Huajin Pharmaceutical Co., Ltd
6.4 Helioeast
6.5 Beijing Wansheng Pharmaceutical Co., Ltd
6.6 Guilin Hwasun Pharmaceutical Co., Ltd
6.7 GuoGuang
7 MAJOR MANUFACTURERS OF GLICLAZIDE IN CHINESE MARKET, 2010-2014
7.1 Servier (Tianjin) Pharmaceutical Co., Ltd
7.2 Servier (France)
7.3 Tianjin Huajin Pharmaceutical Co., Ltd
7.4 NanChang Helioeast Pharmaceutical Co.,Ltd
7.5 Beijing Wansheng Pharmaceutical Co., Ltd
8 MARKET OUTLOOK OF GLICLAZIDE IN CHINA, 2015-2019
8.1 Forecast of Market Size
8.2 Forecast of Competitive Landscape
TABLE OF SELECTED CHARTS
Chart Patent Registration Information of Gliclazide in China
Chart Approval Status of Gliclazide in China
Chart Sales Status of Gliclazide in China, 2010-2014
Chart Sales Value of Gliclazide in China, 2010-2014
Chart Sales Value of Gliclazide by Regions in China, 2010-2014
Chart Sales Value of Gliclazide Tablets in China, 2010-2014
Chart Sales Value of Gliclazide Capsules in China, 2010-2014
Chart Market Share of Major Manufacturers of Gliclazide for Sales Value in China, 2010-2014
Chart Sales Value and Market Share of Gliclazide Made by Servier (Tianjin) Pharmaceutical Co., Ltd, 2010-2014
Chart Sales Value and Market Share of Gliclazide Made by Servier (France), 2010-2014
Chart Sales Value and Market Share of Gliclazide Made by Tianjin Huajin Pharmaceutical Co., Ltd, 2010-2014
Chart Sales Value and Market Share of Gliclazide Made by Helioeast, 2010-2014
Chart Price of Gliclazide Made by Servier (Tianjin) Pharmaceutical Co., Ltd in Some Chinese Cities in 2014
Chart Price of Gliclazide Made by Tianjin Huajin Pharmaceutical Co., Ltd in Some Chinese Cities in 2014
Chart Price of Gliclazide Made by Servier (France) in Some Chinese Cities in 2014
Chart Price of Gliclazide Made by Helioeast in Some Chinese Cities in 2014
1.1 Indication
1.2 Sales Status in Global Market
2 MARKET PROFILE OF GLICLAZIDE IN CHINA
2.1 Patent Status
2.2 Major Manufacturers
2.3 Market Size
3 SURVEY ON SALES STATUS OF GLICLAZIDE IN CHINA, 2010-2014
3.1 Sales Value
3.1.1 Overall Sales Value
3.1.2 Sales Value by Regions
3.2 Sales Volume
3.2.1 Overall Sales Volume
3.2.2 Sales Volume by Regions
4 SURVEY ON MARKET SHARE OF MAJOR MANUFACTURERS OF GLICLAZIDE IN CHINA, 2010-2014
4.1 Market Share by Sales Value
4.2 Market Share by Sales Volume
5 SURVEY ON DOSAGE FORMS OF GLICLAZIDE IN CHINA, 2010-2014
5.1 Share of Different Dosage Forms by Sales Value
5.2 Share of Different Dosage Forms by Sales Volume
6 REFERENCE PRICE OF GLICLAZIDE IN CHINESE HOSPITALS IN 2014
6.1 Servier (Tianjin) Pharmaceutical Co., Ltd (Trade Name: Diamicron)
6.2 Servier (France)
6.3 Tianjin Huajin Pharmaceutical Co., Ltd
6.4 Helioeast
6.5 Beijing Wansheng Pharmaceutical Co., Ltd
6.6 Guilin Hwasun Pharmaceutical Co., Ltd
6.7 GuoGuang
7 MAJOR MANUFACTURERS OF GLICLAZIDE IN CHINESE MARKET, 2010-2014
7.1 Servier (Tianjin) Pharmaceutical Co., Ltd
7.2 Servier (France)
7.3 Tianjin Huajin Pharmaceutical Co., Ltd
7.4 NanChang Helioeast Pharmaceutical Co.,Ltd
7.5 Beijing Wansheng Pharmaceutical Co., Ltd
8 MARKET OUTLOOK OF GLICLAZIDE IN CHINA, 2015-2019
8.1 Forecast of Market Size
8.2 Forecast of Competitive Landscape
TABLE OF SELECTED CHARTS
Chart Patent Registration Information of Gliclazide in China
Chart Approval Status of Gliclazide in China
Chart Sales Status of Gliclazide in China, 2010-2014
Chart Sales Value of Gliclazide in China, 2010-2014
Chart Sales Value of Gliclazide by Regions in China, 2010-2014
Chart Sales Value of Gliclazide Tablets in China, 2010-2014
Chart Sales Value of Gliclazide Capsules in China, 2010-2014
Chart Market Share of Major Manufacturers of Gliclazide for Sales Value in China, 2010-2014
Chart Sales Value and Market Share of Gliclazide Made by Servier (Tianjin) Pharmaceutical Co., Ltd, 2010-2014
Chart Sales Value and Market Share of Gliclazide Made by Servier (France), 2010-2014
Chart Sales Value and Market Share of Gliclazide Made by Tianjin Huajin Pharmaceutical Co., Ltd, 2010-2014
Chart Sales Value and Market Share of Gliclazide Made by Helioeast, 2010-2014
Chart Price of Gliclazide Made by Servier (Tianjin) Pharmaceutical Co., Ltd in Some Chinese Cities in 2014
Chart Price of Gliclazide Made by Tianjin Huajin Pharmaceutical Co., Ltd in Some Chinese Cities in 2014
Chart Price of Gliclazide Made by Servier (France) in Some Chinese Cities in 2014
Chart Price of Gliclazide Made by Helioeast in Some Chinese Cities in 2014
